NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Structured Abstract
Objectives:
To inform future discussions and decisions about how to define treatment-resistant depression (TRD) and specify the important outcomes measured in research studies, and to clarify how trials or observational studies might best be designed and conducted to inform clinical practice and health policy.
Data sources:
To provide a comprehensive understanding of how experts and investigators have defined and studied TRD, we first performed a narrative review of relevant literature. We considered consensus statements, practice guidelines, government materials, and other literature published from 1/1/1995 through 8/18/2017, except for systematic reviews (limited to start 1/1/2005). Next, we performed a systematic review of published studies of TRD interventions (1/1/2005 through 8/18/2017) indexed in MEDLINE®, EMBASE, PsycINFO, and Cochrane Library.
Review methods:
Trained personnel dually reviewed all titles and abstracts for eligibility. Studies marked for possible inclusion by either reviewer and those with inadequate abstracts underwent dual full-text review. Disagreements were resolved by consensus discussion. One member of the research team abstracted data; a senior investigator reviewed abstractions for accuracy and completeness.
Results:
Our narrative review indicated that no consensus definition existed for TRD. We identified four basic definitions for TRD (3 for major depressive disorder [MDD]; 1 for bipolar disorder). Based on frequency of reporting in the literature, the most common TRD definition for MDD required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration. The most common TRD definition for bipolar disorder required one prior treatment failure. For all TRD definitions, no clear consensus emerged on defining adequacy of either dose or duration. Little agreement exists about the best approach to diagnose TRD or the preferred outcome measure, although the Hamilton Depression Rating Scale was the most used. We found general agreement about minimizing bias by using randomization; studies have not focused on minimizing placebo effects. Evidence about the risk factors (e.g., age, sex, number of prior failed treatments, and length of current depressive episode) associated with TRD and data to assess potential prognostic factors were limited.
Only 17 percent of intervention studies enrolled study populations that met frequently specified criteria for TRD. Most studies (88%) were randomized controlled trials; all studies applied some exclusion criteria to limit potential confounders. Depressive outcomes and clinical global impressions were commonly measured; functional impairment and quality-of-life tools were rarely used.
Conclusions:
No agreed-upon definition of TRD exists; although experts may converge on two as the best number of prior treatment failures, they do not agree on definitions for adequacy of either dose or duration or outcomes measures. Critical to advancing TRD research are two key steps: (1) developing a consensus definition of TRD that addresses how best to specify the number of prior treatment failures and the adequacy of dose and duration; and (2) identifying a core package of outcome measures that can be applied in a standardized manner. Our recommendations about stronger approaches to designing and conducting TRD research will foster better evidence to translate into clearer guidelines for treating patients with this serious condition.
Contents
- Preface
- Acknowledgments
- Peer Reviewers
- Evidence Summary
- Background and Objectives
- Methods
- Results: Narrative Review Key Questions
- Introduction
- Results of Literature Searches
- Key Question 1. Definitions of Treatment-Resistant Depression in This Literature Base
- Key Question 2. Diagnostic Tools to Identify TreatmentResistant Depression in Clinical Research
- Key Question 3. Success or Failure of Treatment in Clinical Studies of Treatment-Resistant Depression
- Key Question 4. Types of Research Designs to Study Treatment-Resistant Depression
- Key Question 5. Risk Factors for Treatment-Resistant Depression
- Key Question 6. Patient Characteristics, Approaches to Prior Treatments as Inclusion Criteria, and Elements of Diagnostic Assessments
- Key Question 7. Comparison of Inclusion Criteria With Definition of Treatment-Resistant Depression from Narrative Questions
- Key Question 8. Main Study Designs, Approaches for Run-In or Wash-Out Periods, and Study Durations
- Key Question 9. Risk Factors or Other Patient Characteristics Specifically for Treatment-Resistant Depression
- Key Question 10. What are relationships between risk factors or placebo response on results of studies?
- Key Question 11. Variables or Information Used to Define Endpoints
- Discussion
- References
- Appendix A. Literature Search Strategies and Yields
- Appendix B. Excluded Studies
- Appendix C. Evidence Tables
- Appendix D. Risk of Bias Ratings
Suggested citation:
Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Boland J, Lux L, Weber RP, Randolph C, Bann C, Coker-Schwimmer E, Viswanathan M, Lohr KN. Definition of Treatment-Resistant Depression in the Medicare Population. Technology Assessment Program. Project ID: PSYT0816. (Prepared by RTI—UNC Evidence-Based Practice Center under Contract No. HHSA290201500011I_HHSA29032006T). Rockville, MD: Agency for Healthcare Research and Quality. February 2018. http://www.ahrq.gov/clinic/epcix.htm.
This report is based on research conducted by the RTI-University of North Carolina at Chapel Hill (RTI-UNC) Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA290201500011I_HHSA29032006T). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ and CMS. No statement in this article should be construed as an official position of AHRQ, CMS, or the U.S. Department of Health and Human Services.
None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
Persons using assistive technology may not be able to fully access information in this report. For assistance, contact vog.shh.qrha@cpe.
- NLM CatalogRelated NLM Catalog Entries
- Defining treatment-resistant depression.[Depress Anxiety. 2020]Defining treatment-resistant depression.Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, Boland E, Weber RP, Randolph C, Bann C, et al. Depress Anxiety. 2020 Feb; 37(2):134-145. Epub 2019 Oct 22.
- Definition of treatment-resistant depression - Asia Pacific perspectives.[J Affect Disord. 2019]Definition of treatment-resistant depression - Asia Pacific perspectives.Ng CH, Kato T, Han C, Wang G, Trivedi M, Ramesh V, Shao D, Gala S, Narayanan S, Tan W, et al. J Affect Disord. 2019 Feb 15; 245:626-636. Epub 2018 Nov 5.
- Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force[ 2013]Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task ForceLin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E. 2013 Nov
- Review Telehealth Services Designed for Women: An Evidence Map[ 2017]Review Telehealth Services Designed for Women: An Evidence MapGoldstein KM, Gierisch JM, Zullig LL, Alishahi A, Brearly T, Dedert EA, Raitz G, Sata SS, Whited JD, Bosworth HB, et al. 2017 Nov
- Review Screening and Interventions for Childhood Overweight[ 2005]Review Screening and Interventions for Childhood OverweightWhitlock EP, Williams SB, Gold R, Smith P, Shipman S. 2005 Jul
- Definition of Treatment-Resistant Depression in the Medicare PopulationDefinition of Treatment-Resistant Depression in the Medicare Population
Your browsing activity is empty.
Activity recording is turned off.
See more...